UPS plans to handle nearly 70% of holiday packages through automated sorting, using robots and RFID tags to improve efficiency and reduce labor costs. CEO Carol Tomé highlighted that while package volume is intentionally reduced, especially from Amazon, the company targets higher margins through automation and better pricing. UPS expects a 25% volume increase from Q3 to Q4 but a slight year-over-year decline due to fewer shipments from major customers. The upcoming Q4 earnings report will be crucial to see if UPS can maintain its margin goals and dividend amid these changes.
UPS's plan to automate nearly 70% of holiday packages provides context for industrial sector activity. For readers following Industrials, here is Pluang's market snapshot as of Oct 30, 2026 01:21 WIB: Out of 135 priced US Industrials stocks, 95 rose and 39 fell today. Notable movers include Huntington Ingalls Industries Inc (HII) at USD 313.45 with a 12.24% gain and a typical hold time of 32 days, Honeywell Aerospace Inc. (HONA) at USD 158.81 down 10.29% with a 12-day hold, and Flowserve Corporation (FLS) at USD 78.74 up 9.65% with a 21-day hold and nearly balanced buy/sell activity.
SAP, a global enterprise software leader, will merge its North Texas operations into a new office in Addison, Texas, relocating about 1,000 employees from Plano and Allen. The new Spectrum Center location will house business operations, software deve...
Ipsos has appointed Mitch Barns as Chairman and CEO for the Americas region, effective November 2, 2026. Barns brings extensive leadership experience from his previous roles as Global CEO of Nielsen and CEO of The Opus Group, positioning him to drive...
Polymarket's international prediction market platform experienced an outage after a third-party data provider was hacked, leading to unauthorized withdrawals from user wallets. The company paused trading on the platform, fixed the issue, and plans to...
Mastercard reported robust Q3 results with 14% revenue growth and 21% earnings per share growth, driven by strong operating leverage. Management reaffirmed its guidance and expects continued outperformance. The stock reached a new all-time high, supp...
Cartesian Therapeutics maintains a 'Buy' rating due to progress in its Descartes-08 cell therapy programs, with pivotal phase 3 trial results for Myasthenia Gravis expected in early 2027 and a potential regulatory filing mid-year. The company is also...
